Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 7150391, 14 pages
http://dx.doi.org/10.1155/2016/7150391
Review Article

Research Advances on Hepatotoxicity of Herbal Medicines in China

1Research Center for New Drug Evaluation, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China
2Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
3China Military Institute of Chinese Medicine, Integrative Medical Center, 302 Military Hospital of China, Beijing 10003, China

Received 6 May 2016; Accepted 31 July 2016

Academic Editor: Minjun Chen

Copyright © 2016 Changxiao Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Calitz, L. Du Plessis, C. Gouws et al., “Herbal hepatotoxicity: current status, examples, and challenges,” Expert Opinion on Drug Metabolism and Toxicology, vol. 11, no. 10, pp. 1551–1565, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. S.-J. Oh, J.-H. Cho, and C.-G. Son, “Systematic review of the incidence of herbal drug-induced liver injury in Korea,” Journal of Ethnopharmacology, vol. 159, pp. 253–256, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. N. P. Chalasani, P. H. Hayashi, H. L. Bonkovsky, V. J. Navarro, W. M. Lee, and R. J. Fontana, “ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury,” American Journal of Gastroenterology, vol. 109, no. 7, pp. 950–966, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Danan and C. Benichou, “Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries,” Journal of Clinical Epidemiology, vol. 46, no. 11, pp. 1323–1330, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. V. A. J. Maria and R. M. M. Victorino, “Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis,” Hepatology, vol. 26, no. 3, pp. 664–669, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. D. C. Rockey, L. B. Seeff, J. Rochon et al., “Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method,” Hepatology, vol. 51, no. 6, pp. 2117–2126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Rochon, P. Protiva, L. B. Seeff et al., “Reliability of the roussel uclaf causality assessment method for assessing causality in drug-induced liver injury,” Hepatology, vol. 48, no. 4, pp. 1175–1183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. S. Barritt IV, J. Lee, and P. H. Hayashi, “Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness,” Clinical Gastroenterology and Hepatology, vol. 8, no. 7, pp. 635–637, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. P. A. G. M. De Smet, “Herbal medicine in Europe—relaxing regulatory standards,” New England Journal of Medicine, vol. 352, no. 12, pp. 1176–1178, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Teschke, A. Eickhoff, A. Wolff, C. Frenzel, and J. Schulze, “Herbal hepatotoxicity and WHO global introspection method,” Annals of Hepatology, vol. 12, no. 1, pp. 11–21, 2013. View at Google Scholar · View at Scopus
  11. R. Teschke, R. Bahre, A. Genthner, J. Fuchs, W. Schmidt-Taenzer, and A. Wolff, “Suspected black cohosh hepatotoxicity-challenges and pitfalls of causality assessment,” Maturitas, vol. 63, no. 4, pp. 302–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Teschke, “Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review,” Menopause, vol. 17, no. 2, pp. 426–440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Teschke, C. Frenzel, J. Schulze, and A. Eickhoff, “Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained?” Regulatory Toxicology and Pharmacology, vol. 63, no. 1, pp. 1–9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Teschke, W. Schmidt-Taenzer, and A. Wolff, “USP suspected herbal hepatotoxicity: quality of causality assessment is more important than quantity of counted cases, not vice versa,” Pharmacoepidemiology and Drug Safety, vol. 21, no. 3, pp. 336–338, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Wang, Z. Ma, M. Niu et al., “Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum,” Frontiers of Medicine, vol. 9, no. 4, pp. 457–467, 2015. View at Publisher · View at Google Scholar
  16. B. Valdivia-Correa, C. Gómez-Gutiérrez, M. Uribe, and N. Méndez-Sánchez, “Herbal medicine in Mexico: a cause of hepatotoxicity. A critical review,” International Journal of Molecular Sciences, vol. 17, no. 2, article 235, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Wang, Y. Zhao, X. Xiao et al., “Assessment of the renal protection and hepatotoxicity of rhubarb extract in rats,” Journal of Ethnopharmacology, vol. 124, no. 1, pp. 18–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G.-A. Bounda and Y. Feng, “Review of clinical studies of Polygonum multiflorum Thunb. and its isolated bioactive compounds,” Pharmacognosy Research, vol. 7, no. 3, pp. 225–236, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Y. Li, Y. Li, and X. H. Xiao, “Research status of herbal drug-induced liver injury,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 24, no. 3, pp. 265–268, 2008. View at Google Scholar
  20. K. T. Howitz, K. J. Bitterman, H. Y. Cohen et al., “Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan,” Nature, vol. 425, no. 6954, pp. 191–196, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. B. P. Hubbard, A. P. Gomes, H. Dai et al., “Evidence for a common mechanism of SIRT1 regulation by allosteric activators,” Science, vol. 339, no. 6124, pp. 1216–1219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Morselli, M. C. Maiuri, M. Markaki et al., “Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy,” Cell Death and Disease, vol. 1, no. 1, article e10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J.-B. Wang, X.-H. Xiao, X.-X. Du, Z.-S. Zou, H.-B. Song, and X.-X. Guo, “Identification and early diagnosis for traditional Chinese medicine-induced liver injury based on translational toxicology,” China Journal of Chinese Materia Medica, vol. 39, no. 1, pp. 5–9, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Teschke, A. Wolff, C. Frenzel, and J. Schulze, “Review article: herbal hepatotoxicity—an update on traditional Chinese medicine preparations,” Alimentary Pharmacology and Therapeutics, vol. 40, no. 1, pp. 32–50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Zhu, M. Niu, J. Chen et al., “Hepatobiliary and pancreatic: comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients,” Journal of Gastroenterology and Hepatology, vol. 31, no. 8, pp. 1476–1482, 2016. View at Publisher · View at Google Scholar
  26. Y. Zhou, L. Yang, Z. Liao, X. He, Y. Zhou, and H. Guo, “Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21 789 patients,” European Journal of Gastroenterology and Hepatology, vol. 25, no. 7, pp. 825–829, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. V. J. Navarro, H. Barnhart, H. L. Bonkovsky et al., “Liver injury from herbals and dietary supplements in the U.S. drug-induced liver injury network,” Hepatology, vol. 60, no. 4, pp. 1399–1408, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Chalasani, H. L. Bonkovsky, R. Fontana et al., “Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study,” Gastroenterology, vol. 148, no. 7, pp. 1340.e7–1352.e7, 2015. View at Publisher · View at Google Scholar
  29. K. T. Suk, D. J. Kim, C. H. Kim et al., “A prospective nationwide study of drug-induced liver injury in Korea,” American Journal of Gastroenterology, vol. 107, no. 9, pp. 1380–1387, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Takikawa, Y. Murata, N. Horiike, H. Fukui, and M. Onji, “Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006,” Hepatology Research, vol. 39, no. 5, pp. 427–431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. Chinese Medical Association, “Hepatobiliary disease Digestive Disease Collaborative Group. National multi-center drug-induced acute liver injury in patients hospitalized research and analysis,” Chinese Journal of Digestion, vol. 27, no. 7, pp. 439–442, 2007. View at Google Scholar
  32. Y. M. Chen, B. Chang, D. Zhang et al., “Cause of drug-induced liver injury and type of injury in Shenyang region,” World Chinese Journal of Digestology, vol. 16, no. 22, pp. 2525–2528, 2008. View at Google Scholar
  33. Y. Zhu, Y. G. Li, G. Wang et al., “Clinical analysis of 595 cases of Chinese medicine cause drug-induced liver injury,” Chinese Journal of Integrative Medicine, vol. 36, no. 1, pp. 38–42, 2016. View at Google Scholar
  34. G. Lin, J. Y. Wang, N. Li et al., “Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum,” Journal of Hepatology, vol. 54, no. 4, pp. 666–673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. W. L. Deng, “Research Report Tripterygium poisoning and toxicity,” TCM Pharmacology Clinic, vol. 17, no. 3, pp. 42–47, 2001. View at Google Scholar
  36. R. Teschke, “Traditional Chinese medicine induced liver injury,” Journal of Clinical and Translational Hepatology, vol. 2, pp. 80–94, 2014. View at Google Scholar
  37. Z. Tu, B. Q. Jiang, Y. L. Zhao et al., “Comparing liver injury in rat and sensitive indicator of screening around Polygonum processing,” China Journal of Chinese Materia Medica, vol. 40, no. 4, pp. 654–660, 2015. View at Google Scholar
  38. T. Efferth and B. Kaina, “Toxicities by herbal medicines with emphasis to traditional Chinese medicine,” Current Drug Metabolism, vol. 12, no. 10, pp. 989–996, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Stickel and D. Shouval, “Hepatotoxicity of herbal and dietary supplements: an update,” Archives of Toxicology, vol. 89, no. 6, pp. 851–865, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Y. Hu and P. Huang, “Herbal medicines and drug-induced liver injury,” Chinese Journal of Hepatology, vol. 20, no. 3, pp. 173–175, 2012. View at Google Scholar
  41. V. J. Navarro and M. I. Lucena, “Hepatotoxicity induced by herbal and dietary supplements,” Seminars in Liver Disease, vol. 34, no. 2, pp. 172–193, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Ostapowicz, R. J. Fontana, F. V. Schioødt et al., “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States,” Annals of Internal Medicine, vol. 137, no. 12, pp. 947–954, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. K. T. Suk and D. J. Kim, “Drug-induced liver injury: present and future,” Clinical and Molecular Hepatology, vol. 18, no. 3, pp. 249–257, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. J. S. Au, V. J. Navarro, and S. Rossi, “Review article: drug-induced liver injury—its pathophysiology and evolving diagnostic tools,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 1, pp. 11–20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. R. J. Andrade, M. I. Lucena, M. C. Fernández et al., “Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period,” Gastroenterology, vol. 129, no. 2, pp. 512–521, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Chalasani, R. J. Fontana, H. L. Bonkovsky et al., “Causes, clinical features, and outcomes from a Prospective Study of drug-induced liver injury in the United States,” Gastroenterology, vol. 135, no. 6, pp. 1924–1934.e4, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. M. B. De Valle, V. Av Klinteberg, N. Alem, R. Olsson, and E. Björnsson, “Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 8, pp. 1187–1195, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Teschke, J. Schulze, A. Schwarzenboeck, A. Eickhoff, and C. Frenzel, “Herbal hepatotoxicity: suspected cases assessed for alternative causes,” European Journal of Gastroenterology and Hepatology, vol. 25, no. 9, pp. 1093–1098, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Bunchorntavakul and K. R. Reddy, “Review article: herbal and dietary supplement hepatotoxicity,” Alimentary Pharmacology and Therapeutics, vol. 37, no. 1, pp. 3–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. B. M. Lee, W. C. Lee, J. Y. Jang et al., “Clinical features of drug-induced liver injury according to etiology,” Journal of Korean Medical Science, vol. 30, no. 12, pp. 1815–1820, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Raschi and F. de Ponti, “Drug- and herb-induced liver injury: progress, current challenges and emerging signals of post-marketing risk,” World Journal of Hepatology, vol. 7, no. 13, pp. 1761–1771, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. J. B. Wang, C. Y. Li, H. B. Song, Z. F. Ban, and X. H. Xiao, “Integrated evidence chain-based identification of Chinese herbal medicine-induced hepatotoxicity and rational usage: exemplification by Polygonumultiflorum (Heshouwu),” Chinese Science Bulletin, vol. 61, no. 9, pp. 971–980, 2016. View at Google Scholar
  53. The Chinese Traditional Medical Association, Guidelines for Diagnosis and Treatment of Herb-Induced Liver Injury, The Chinese Traditional Medical Association, Beijing, China, 2016.
  54. W. B. Hou, X. F. Xiao, W. Guo, and T. J. Zhang, “Advances in studies on chemistry, pharmacological effect, and pharmacokinetics of eurycomalongifolia,” Chinese Herbal Medicines, vol. 3, no. 3, pp. 186–195, 2011. View at Google Scholar
  55. S. Tian, L. D. Du, S. B. Wang et al., “Pharmacokinetic study of baicalein and its major metabolites after iv administration in dogs,” Chinese Herbal Medicines, vol. 3, no. 3, pp. 196–201, 2011. View at Google Scholar
  56. S. W. Ma, M. Zhao, H. X. Liu, L. Y. Wang, and X. T. Zhang, “Pharmacokinetic Effects of Baicalin on Cerebral Ischemia-reperfusion after iv Administration in Rats,” Chinese Herbal Medicines, vol. 4, no. 1, pp. 53–57, 2012. View at Google Scholar
  57. K. P. Liu, L. F. Wang, Y. Li, B. Yang, C. Du, and Y. Wang, “Preparation, pharmacokinetics, and tissue distribution properties of icariin-loaded stealth solid lipid nanoparticles in mice,” Chinese Herbal Medicines, vol. 4, no. 2, pp. 170–174, 2012. View at Google Scholar
  58. J. L. Lv, S. Y. Jin, H. L. Yuan et al., “Rational daily administration times of yinchenhao decoction in rats with jaundice based on PD/PK,” Chinese Herbal Medicines, vol. 4, no. 2, pp. 150–156, 2012. View at Google Scholar
  59. G. Ai, Z. M. Huang, and C. X. Liu, “Pharmacokinetic study on hyperoside in Beagle’s dogs,” Chinese Herbal Medicines, vol. 4, no. 3, pp. 213–217, 2012. View at Google Scholar
  60. “Assay-Ready Expanded Human Hepatocytes,” https://www.axolbio.com/page/hepatocytes.
  61. W. M. Cassidy and T. B. Reynolds, “Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury,” Journal of Clinical Gastroenterology, vol. 19, no. 2, pp. 118–121, 1994. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Laine, L. Goldkind, S. P. Curtis, L. G. Connors, Z. Yanqiong, and C. P. Cannon, “How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial,” American Journal of Gastroenterology, vol. 104, no. 2, pp. 356–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Mueller, G. Tascher, G. Damm, A. K. Nüssler, E. Heinzle, and F. Noor, “Real-time in situ viability assessment in a 3D bioreactor with liver cells using resazurin assay,” Cytotechnology, vol. 65, no. 2, pp. 297–305, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. B. C. Fox, A. S. Devonshire, M. E. Schutte et al., “Validation of reference gene stability for APAP hepatotoxicity studies in different in vitro systems and identification of novel potential toxicity biomarkers,” Toxicology in Vitro, vol. 24, no. 7, pp. 1962–1970, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Xiong, F. Yang, L. Fang et al., “Metabolomic and genomic evidence for compromised bile acid homeostasis by senecionine, a hepatotoxic pyrrolizidine alkaloid,” Chemical Research in Toxicology, vol. 27, no. 5, pp. 775–786, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. S. A. Hoffmann, U. Müller-Vieira, K. Biemel et al., “Analysis of drug metabolism activities in a miniaturized liver cell bioreactor for use in pharmacological studies,” Biotechnology and Bioengineering, vol. 109, no. 12, pp. 3172–3181, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. F. Knöspel, F. Jacobs, N. Freyer et al., “In vitro model for hepatotoxicity studies based on primary human hepatocyte cultivation in a perfused 3D bioreactor system,” International Journal of Molecular Sciences, vol. 17, no. 4, article 584, 2016. View at Publisher · View at Google Scholar
  68. C. Aninat, A. Piton, D. Glaise et al., “Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells,” Drug Metabolism and Disposition, vol. 34, no. 1, pp. 75–83, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. A. L. Hopkins, “Network pharmacology,” Nature Biotechnology, vol. 25, no. 10, pp. 1110–1111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. C.-X. Liu, R. Liu, H.-R. Fan et al., “Network pharmacology bridges traditional application and modern development of traditional Chinese medicine,” Chinese Herbal Medicines, vol. 7, no. 1, pp. 3–17, 2015. View at Publisher · View at Google Scholar
  72. Y. Liu, N. Ai, A. Keys, X. Fan, and M. Chen, “Network pharmacology for traditional Chinese Medicine Research: methodologies and applications,” Chinese Herbal Medicines, vol. 7, no. 1, pp. 18–26, 2015. View at Publisher · View at Google Scholar
  73. X. Zhang, H. R. Fan, Y. Z. Li et al., “Development and application of network toxicology in safety research of Chinese Materia Medica,” Chinese Herbal Medicines, vol. 7, no. 1, pp. 27–38, 2015. View at Publisher · View at Google Scholar
  74. X. Fan, X. Zhao, Y. Jin, X. Shen, and C. Liu, “Network toxicology and its application to traditional Chinese medicine,” China Journal of Chinese Meteria Medica, vol. 36, no. 21, pp. 2920–2922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. W. Zhu, D. M. Wang, Y. J. Xu, and C. J. Lu, “Establishing concept of computer networks herbal pharmacology online database,” Journal of Guangzhou University of Traditional Chinese Medicine, vol. 30, no. 1, pp. 109–111, 2013. View at Google Scholar
  76. P. Muñetón-Pérez, “Medicinal plants: a vital complement to the health of mexicans,” Revista Digital Universitaria, vol. 10, no. 9, 2009. View at Google Scholar
  77. A. Aguilar, J. R. Camacho, S. Chino, P. Jáquez, and E. López, “Herbal medicinal Mexican Social Security Institute,” MexicanSocialSecurityInstitute(MSSI), http://www.Medicinatradicionalmexicana.unam.mx/presenta.html.
  78. T. D. Schiano, “Hepatotoxicity and complementary and alternative medicines,” Clinics in Liver Disease, vol. 7, no. 2, pp. 453–473, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. K. T. Suk, D. J. Kim, C. H. Kim et al., “A prospective nationwide study of drug-induced liver injury in Korea,” The American Journal of Gastroenterology, vol. 107, no. 9, pp. 1380–1387, 2012. View at Publisher · View at Google Scholar · View at Scopus